F
Fate Therapeutics, Inc. (FATE)
NGM – Real Time Price. Currency in USD
2.25
+0.07 (3.21%)
At close: May 12, 2026, 4:00 PM EDT
2.18
-0.07 (-3.11%)
After-hours: May 12, 2026, 7:53 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
2.25
+0.07 (3.21%)
At close: May 12, 2026, 4:00 PM EDT
2.18
-0.07 (-3.11%)
After-hours: May 12, 2026, 7:53 PM EDT
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Bahram Valamehr M.B.A., Ph.D. | President, CEO & Director |
| Dr. Martin Hosking | Head of Research |
| Dr. Tunde Babalola Ph.D. | Senior Vice President of Technical Operations & Quality |
| Dr. Yu Cai J.D., Ph.D. | Head of Intellectual Property & Assistant General Counsel |
| Mr. Andrew Henry | Senior Vice President of Clinical Operations |
| Mr. Kamal Adawi M.S., MBA | CFO & Treasurer |
| Mr. Ryan Douglas | Senior Director of Investor Relations & Business Development |
| Ms. Cindy R. Tahl J.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Ms. Jessica Francis | Senior Vice President of Human Resources & Operations |
| Ms. Kate Duvall | Corporate Controller |
| Date | Type | Document |
|---|---|---|
| 2026-04-24 | DEFA14A | d97851ddefa14a.htm |
| 2026-04-24 | ARS | d99485dars.pdf |
| 2026-02-26 | 8-K | fate-20260226.htm |
| 2026-02-26 | 10-K | fate-20251231.htm |
| 2025-11-13 | 10-Q | fate-20250930.htm |
| 2025-10-27 | 8-K | d36426d8k.htm |
| 2025-10-20 | S-8 | d40313ds8.htm |
| 2025-10-14 | 8-K | fate-20251010.htm |
| 2025-08-12 | 8-K | d452012d8k.htm |
| 2025-06-17 | 8-K/A | d35713d8ka.htm |